Tags Archive Navigation
icon
-
Media ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease